This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
Xiaoyan Li, PhD
Advertisement
Articles by Xiaoyan Li, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Special Report: The Oncology Care Model, 10 Years Later
2
Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD
3
FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19
4
Patients on GLP-1s Increasingly Carry Diagnoses for New Indications
5